| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| PPAR alpha | 16 | 2023 | 55 | 4.130 |
Why?
|
| Hippocampus | 14 | 2023 | 262 | 2.560 |
Why?
|
| Up-Regulation | 16 | 2022 | 150 | 2.440 |
Why?
|
| Mice | 41 | 2023 | 1345 | 1.680 |
Why?
|
| Animals | 47 | 2023 | 3510 | 1.450 |
Why?
|
| Gene Expression Regulation | 8 | 2021 | 262 | 1.340 |
Why?
|
| Memory | 6 | 2018 | 296 | 1.210 |
Why?
|
| Dopaminergic Neurons | 8 | 2022 | 44 | 1.170 |
Why?
|
| Parkinson Disease | 9 | 2020 | 776 | 1.120 |
Why?
|
| Neurons | 13 | 2020 | 315 | 1.110 |
Why?
|
| alpha-Synuclein | 5 | 2022 | 115 | 1.100 |
Why?
|
| Disease Models, Animal | 16 | 2022 | 584 | 1.050 |
Why?
|
| Mice, Inbred C57BL | 24 | 2023 | 405 | 1.000 |
Why?
|
| Neuronal Plasticity | 5 | 2019 | 45 | 0.890 |
Why?
|
| Oleic Acids | 2 | 2021 | 5 | 0.860 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 8 | 2019 | 34 | 0.860 |
Why?
|
| Promoter Regions, Genetic | 4 | 2021 | 89 | 0.830 |
Why?
|
| Signal Transduction | 9 | 2021 | 410 | 0.760 |
Why?
|
| Substantia Nigra | 10 | 2022 | 111 | 0.760 |
Why?
|
| Parkinsonian Disorders | 7 | 2021 | 210 | 0.750 |
Why?
|
| Alzheimer Disease | 11 | 2023 | 1962 | 0.750 |
Why?
|
| Sleep Aids, Pharmaceutical | 1 | 2021 | 2 | 0.730 |
Why?
|
| Food Additives | 1 | 2021 | 7 | 0.720 |
Why?
|
| Microglia | 8 | 2018 | 133 | 0.720 |
Why?
|
| Sodium Chloride | 3 | 2014 | 32 | 0.660 |
Why?
|
| Oxygen | 3 | 2014 | 74 | 0.650 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 5 | 2023 | 60 | 0.640 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 80 | 0.600 |
Why?
|
| Nitric Oxide | 4 | 2013 | 75 | 0.600 |
Why?
|
| Cinnamomum zeylanicum | 6 | 2020 | 22 | 0.590 |
Why?
|
| Nerve Growth Factors | 2 | 2015 | 37 | 0.580 |
Why?
|
| Simvastatin | 2 | 2015 | 14 | 0.580 |
Why?
|
| Astrocytes | 5 | 2021 | 141 | 0.570 |
Why?
|
| CD11b Antigen | 2 | 2008 | 14 | 0.570 |
Why?
|
| Neuroglia | 4 | 2019 | 47 | 0.560 |
Why?
|
| Hydroxybutyrates | 1 | 2016 | 7 | 0.540 |
Why?
|
| Neurodegenerative Diseases | 5 | 2013 | 117 | 0.530 |
Why?
|
| Basal Ganglia | 1 | 2016 | 15 | 0.520 |
Why?
|
| Sodium Benzoate | 4 | 2019 | 19 | 0.520 |
Why?
|
| Phenylbutyrates | 2 | 2013 | 7 | 0.510 |
Why?
|
| Brain-Derived Neurotrophic Factor | 3 | 2020 | 46 | 0.480 |
Why?
|
| Brain | 8 | 2021 | 1560 | 0.480 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 53 | 0.470 |
Why?
|
| Synaptic Transmission | 1 | 2014 | 23 | 0.460 |
Why?
|
| Aspirin | 3 | 2019 | 74 | 0.460 |
Why?
|
| Gemfibrozil | 5 | 2021 | 29 | 0.460 |
Why?
|
| Adipose Tissue | 1 | 2015 | 69 | 0.450 |
Why?
|
| Interleukin-12 Subunit p40 | 3 | 2022 | 22 | 0.450 |
Why?
|
| Ankyrin Repeat | 1 | 2013 | 2 | 0.440 |
Why?
|
| Response Elements | 1 | 2013 | 15 | 0.440 |
Why?
|
| Repressor Proteins | 1 | 2013 | 36 | 0.430 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2013 | 25 | 0.430 |
Why?
|
| Reactive Oxygen Species | 3 | 2015 | 103 | 0.420 |
Why?
|
| Neuroprotective Agents | 4 | 2021 | 51 | 0.400 |
Why?
|
| Neurotrophin 3 | 2 | 2013 | 4 | 0.400 |
Why?
|
| Antioxidants | 1 | 2012 | 57 | 0.390 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 249 | 0.390 |
Why?
|
| NF-kappa B | 5 | 2012 | 96 | 0.380 |
Why?
|
| Cells, Cultured | 9 | 2020 | 495 | 0.380 |
Why?
|
| Peptides | 4 | 2018 | 104 | 0.370 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 3 | 2021 | 25 | 0.370 |
Why?
|
| Multiple Sclerosis | 3 | 2023 | 93 | 0.360 |
Why?
|
| Mice, Transgenic | 8 | 2020 | 217 | 0.360 |
Why?
|
| Mice, Knockout | 4 | 2021 | 284 | 0.350 |
Why?
|
| Chemokine CCL5 | 3 | 2019 | 14 | 0.330 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 2 | 2019 | 7 | 0.310 |
Why?
|
| Palmitic Acids | 2 | 2020 | 7 | 0.310 |
Why?
|
| Myelin Basic Protein | 2 | 2009 | 22 | 0.310 |
Why?
|
| Th2 Cells | 2 | 2007 | 15 | 0.310 |
Why?
|
| Cinnamates | 2 | 2018 | 8 | 0.310 |
Why?
|
| Integrins | 1 | 2007 | 11 | 0.290 |
Why?
|
| Humans | 22 | 2023 | 25692 | 0.280 |
Why?
|
| Protein Binding | 3 | 2020 | 116 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 185 | 0.260 |
Why?
|
| Male | 16 | 2020 | 13917 | 0.250 |
Why?
|
| Nootropic Agents | 2 | 2016 | 14 | 0.250 |
Why?
|
| Learning | 2 | 2016 | 67 | 0.250 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2013 | 66 | 0.230 |
Why?
|
| Adaptive Immunity | 3 | 2022 | 18 | 0.220 |
Why?
|
| PPAR-beta | 1 | 2023 | 11 | 0.220 |
Why?
|
| Transcription Factors | 2 | 2021 | 158 | 0.210 |
Why?
|
| Th17 Cells | 2 | 2020 | 25 | 0.210 |
Why?
|
| Physical Conditioning, Animal | 1 | 2022 | 7 | 0.200 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2022 | 24 | 0.200 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 14 | 0.190 |
Why?
|
| Plaque, Amyloid | 2 | 2019 | 138 | 0.190 |
Why?
|
| MPTP Poisoning | 2 | 2019 | 13 | 0.180 |
Why?
|
| Calcium | 2 | 2014 | 364 | 0.180 |
Why?
|
| Inflammation Mediators | 4 | 2016 | 65 | 0.180 |
Why?
|
| Dopamine | 3 | 2013 | 85 | 0.180 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2020 | 14 | 0.180 |
Why?
|
| Cell Differentiation | 1 | 2021 | 127 | 0.170 |
Why?
|
| Lipopolysaccharides | 3 | 2018 | 108 | 0.170 |
Why?
|
| Hypolipidemic Agents | 2 | 2012 | 25 | 0.170 |
Why?
|
| Chemokine CCL11 | 2 | 2017 | 9 | 0.170 |
Why?
|
| Cell Line | 4 | 2019 | 268 | 0.160 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2019 | 12 | 0.160 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2019 | 5 | 0.160 |
Why?
|
| Serine Proteases | 1 | 2019 | 5 | 0.160 |
Why?
|
| Aminopeptidases | 1 | 2019 | 6 | 0.160 |
Why?
|
| Butyrates | 1 | 2019 | 23 | 0.160 |
Why?
|
| Plant Extracts | 2 | 2016 | 14 | 0.160 |
Why?
|
| Rotenone | 1 | 2018 | 10 | 0.160 |
Why?
|
| Corpus Striatum | 1 | 2019 | 60 | 0.160 |
Why?
|
| Antiparkinson Agents | 1 | 2019 | 61 | 0.160 |
Why?
|
| Lysosomes | 1 | 2018 | 21 | 0.160 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 30 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 100 | 0.150 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2018 | 13 | 0.150 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2018 | 28 | 0.150 |
Why?
|
| Synapses | 2 | 2018 | 32 | 0.150 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 72 | 0.140 |
Why?
|
| Sleep | 1 | 2021 | 316 | 0.140 |
Why?
|
| Disease Progression | 4 | 2017 | 664 | 0.140 |
Why?
|
| Female | 12 | 2022 | 14273 | 0.140 |
Why?
|
| Maze Learning | 2 | 2015 | 15 | 0.140 |
Why?
|
| Administration, Oral | 4 | 2020 | 103 | 0.140 |
Why?
|
| Motor Activity | 4 | 2013 | 304 | 0.140 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 35 | 0.140 |
Why?
|
| Ligands | 1 | 2016 | 37 | 0.140 |
Why?
|
| STAT6 Transcription Factor | 1 | 2016 | 9 | 0.140 |
Why?
|
| Food Preservatives | 1 | 2016 | 9 | 0.130 |
Why?
|
| Down-Regulation | 2 | 2013 | 94 | 0.130 |
Why?
|
| Models, Molecular | 1 | 2016 | 79 | 0.130 |
Why?
|
| Macaca mulatta | 2 | 2013 | 60 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 167 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 29 | 0.130 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2016 | 5 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 325 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 86 | 0.130 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2015 | 4 | 0.120 |
Why?
|
| Mice, Mutant Strains | 1 | 2015 | 24 | 0.120 |
Why?
|
| Enzyme Activation | 2 | 2012 | 108 | 0.120 |
Why?
|
| Cytokines | 2 | 2018 | 212 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2015 | 36 | 0.120 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2014 | 4 | 0.120 |
Why?
|
| Nanotechnology | 1 | 2014 | 8 | 0.110 |
Why?
|
| Castration | 1 | 2013 | 5 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2015 | 160 | 0.110 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 100 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2018 | 284 | 0.100 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2012 | 2 | 0.100 |
Why?
|
| Mevalonic Acid | 1 | 2012 | 7 | 0.100 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2012 | 14 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 140 | 0.090 |
Why?
|
| Interleukin-23 | 2 | 2022 | 18 | 0.090 |
Why?
|
| Interleukin-12 | 2 | 2022 | 33 | 0.090 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 155 | 0.090 |
Why?
|
| Inflammation | 3 | 2018 | 261 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 20 | 0.080 |
Why?
|
| Protein Multimerization | 1 | 2009 | 17 | 0.080 |
Why?
|
| Adoptive Transfer | 1 | 2009 | 26 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2022 | 100 | 0.080 |
Why?
|
| RNA, Double-Stranded | 1 | 2008 | 3 | 0.080 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2008 | 13 | 0.080 |
Why?
|
| Hydrogen Peroxide | 1 | 2008 | 36 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 103 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2007 | 4 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 26 | 0.070 |
Why?
|
| Cell Separation | 1 | 2007 | 28 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2007 | 31 | 0.070 |
Why?
|
| Antibodies, Blocking | 2 | 2016 | 6 | 0.070 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2006 | 2 | 0.070 |
Why?
|
| Cyclic GMP | 1 | 2006 | 6 | 0.070 |
Why?
|
| Oxazines | 1 | 2006 | 6 | 0.070 |
Why?
|
| Oxadiazoles | 1 | 2006 | 8 | 0.070 |
Why?
|
| Interferon-gamma | 2 | 2022 | 75 | 0.070 |
Why?
|
| HIV-1 | 1 | 2008 | 221 | 0.060 |
Why?
|
| Aging | 1 | 2013 | 1429 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 182 | 0.060 |
Why?
|
| Valerates | 1 | 2023 | 3 | 0.050 |
Why?
|
| Muscles | 1 | 2023 | 56 | 0.050 |
Why?
|
| Proteomics | 1 | 2023 | 85 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 10 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2022 | 25 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2022 | 37 | 0.050 |
Why?
|
| Spleen | 1 | 2022 | 32 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2012 | 51 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2022 | 53 | 0.050 |
Why?
|
| Macrophages | 1 | 2022 | 97 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2C8 Inhibitors | 1 | 2021 | 3 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 201 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2023 | 383 | 0.040 |
Why?
|
| Pars Compacta | 1 | 2019 | 2 | 0.040 |
Why?
|
| Plant Bark | 1 | 2019 | 3 | 0.040 |
Why?
|
| Biotransformation | 1 | 2019 | 6 | 0.040 |
Why?
|
| Fenofibrate | 1 | 2019 | 4 | 0.040 |
Why?
|
| Rotarod Performance Test | 1 | 2019 | 8 | 0.040 |
Why?
|
| Exploratory Behavior | 1 | 2019 | 9 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 31 | 0.040 |
Why?
|
| Nerve Degeneration | 1 | 2019 | 41 | 0.040 |
Why?
|
| Base Sequence | 1 | 2019 | 90 | 0.040 |
Why?
|
| Lewy Bodies | 1 | 2020 | 171 | 0.040 |
Why?
|
| Neuronal Ceroid-Lipofuscinoses | 1 | 2019 | 7 | 0.040 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 2 | 2009 | 20 | 0.040 |
Why?
|
| CREB-Binding Protein | 1 | 2018 | 6 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 38 | 0.040 |
Why?
|
| Transfection | 1 | 2018 | 112 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 51 | 0.030 |
Why?
|
| Myelin Proteolipid Protein | 1 | 2016 | 8 | 0.030 |
Why?
|
| Aged | 3 | 2016 | 8501 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 23 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 187 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 2018 | 315 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2016 | 71 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 4459 | 0.030 |
Why?
|
| Adult | 2 | 2020 | 7336 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2015 | 27 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2015 | 93 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 13 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 37 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 123 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2014 | 140 | 0.030 |
Why?
|
| Neostriatum | 1 | 2013 | 12 | 0.030 |
Why?
|
| Testosterone | 1 | 2013 | 26 | 0.030 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2013 | 49 | 0.030 |
Why?
|
| Formates | 1 | 2013 | 2 | 0.030 |
Why?
|
| Cell Shape | 1 | 2013 | 8 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 33 | 0.030 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2013 | 8 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2013 | 23 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 341 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2013 | 36 | 0.030 |
Why?
|
| Fetus | 1 | 2013 | 37 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2013 | 42 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2013 | 50 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2013 | 134 | 0.030 |
Why?
|
| Middle Aged | 2 | 2016 | 8403 | 0.030 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2012 | 5 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2012 | 8 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 3 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2012 | 4 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 11 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 32 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 41 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 137 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 169 | 0.020 |
Why?
|
| Pravastatin | 1 | 2009 | 10 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2009 | 17 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 110 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2009 | 13 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 88 | 0.020 |
Why?
|
| Mesencephalon | 1 | 2007 | 19 | 0.020 |
Why?
|
| Binding Sites | 1 | 2007 | 65 | 0.020 |
Why?
|
| GATA3 Transcription Factor | 1 | 2007 | 4 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2007 | 20 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2007 | 23 | 0.020 |
Why?
|
| Cognitive Dysfunction | 1 | 2015 | 1017 | 0.020 |
Why?
|